Study Finds Increased Risk of MGUS in Vietnam Vets Exposed to Agent Orange
the ONA take:
Vietnam War veterans exposed to Agent Orange, an herbicidal agent used for warfare, have more than a 2-fold increased risk for monoclonal gammopathy of undetermined significance (MGUS), according to a new study published online ahead of print in JAMA Oncology.
MGUS is a precursor to multiple myeloma. Patients with MGUS have lower antibody levels, plasma cells in the bone marrow, and no symptoms. Therefore, no treatment is indicated for patients with MGUS, but patients should be followed up every 6 months to determine if MGUS has transformed into multiple myeloma or a similar lymphoproliferative disorder.
For the study, a team of researchers led by Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York analyzed samples from 958 male veterans of the Vietnam War. Half of those were Operation Ranch Hand veterans who participated in aerial Agent Orange spray missions.
"Our findings of increased MGUS risk among Ranch Hand veterans support an association between Agent Orange exposure and multiple myeloma," the study concludes.
Agent Orange was widely used during the Vietnam War.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
- Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma
- Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|